Lokavant, a leader in clinical trial intelligence, has just launched Spectrum, a cutting-edge AI software designed to revolutionize clinical trial feasibility and optimization.
Hikma Pharmaceuticals PLC has made a significant announcement, marking the US launch of Combogesic IV, an intravenous, opioid-free pain relief medication providing a multimodal approach to managing pain in adults.
In a groundbreaking development, Systech, a subsidiary of Markem-Imaje and Dover, has introduced a turnkey manual aggregation and rework solution tailored for pharmaceutical manufacturers, CMOs, CDMOs, re-packagers, and wholesalers.
In an inspiring conversation with Liza Laws, Dr. Michael Giles, MD, and chief executive officer of Sonara Health, shares the innovative journey of creating a platform to enhance the accessibility of methadone treatment for opioid use disorder patients.
Yesterday (June 5) CluePoints, providers of established statistical and AI-driven software solutions, and the Food and Drug Administration (FDA) announced an extension to their long-standing collaboration.
As Roquette's US Innovation Center marks its first anniversary, Roquette took the opportunity to reflect on its interesting journey and achievements over the past year.
As the DIA conference in San Diego approaches, Outsourcing Pharma secured an exclusive preview with François Torche, chief product & technology officer and co-founder of CluePoints
As DIA's 60th anniversary at the annual event in San Diego approaches, OSP is excited to bring you insights from Advarra, a leader in advancing clinical research.
Get ready for a big reveal at the DIA conference in San Diego as GiftHealth introduces its latest AI-enabled features designed to revolutionize patient care.
As the anticipation for the 60th DIA annual meeting reaches a fever pitch, eyes should be on Qinecsa, the latest breakthrough in clinical research technology.
At the DIA 2024 Global Annual Meeting, Phastar iwill be proud to join a diverse group of stakeholders from industry, regulatory bodies, academia, and patient communities.
Stella Vnook has founded several biotech companies, including Oral BioLife, a biotechnology firm specializing in pioneering therapies for dental diseases.
Shionogi is stepping up its game in the fight against infectious diseases by opening its first discovery lab in the US, in sunny San Diego, California.
Mirum Pharmaceuticals just got a major boost as the European Committee for Medicinal Products for Human Use (CHMP) gave a positive nod to Livmarli (maralixibat) oral solution for treating Progressive Familial Intrahepatic Cholestasis (PFIC) in patients...
In celebration of Clinical Trials Day last month, OSP sat down with Diane Lacroix, vice president of clinical data management at eClinical Solutions, to delve into the latest advancements and future directions in clinical trials.
In a collaboration set to alter the landscape of clinical trials, Medable Inc. and Masimo have announced a strategic partnership aimed at revolutionizing evidence generation in medical research.
In a resounding declaration of commitment to women’s health, Discovery Park, Kent’s well-known life science and innovation community, has unveiled its latest cohort of trailblazing FemTech start-ups.
In an intriguing interview with Cybin’s CEO, Doug Drysdale, OSP senior editor, Liza Laws found out how second-generation psychedelics could be the biggest breakthrough in psychiatry in 40 years.
UK based Celadon Pharmaceuticals Plc, that specializes in the development, production, and sale of breakthrough cannabis-based medicines, announced that it has begun shipping to the US.
This funding round includes participation from both new and existing accredited investors, reinforcing confidence in Bicycle's innovative approach to precision-guided therapeutics.
A new report from Access to Medicine Foundation gives the advice to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance.
Can Montreal's Centech startup, Install-VASc, transform ultrasound-guided catheter insertion?
Continuing the Montreal startup ideas presented to OSP and others during a recent trip, this was another idea to come from Centech, the non-profit organization helping people develop their ideas in a bid to making them a reality.
Pam Diamond spent almost three decades practicing medicine and looking at problems in the clinical research arena before changing tack so she could make a bigger impact.
A ‘transformational’ treatment for people with severe alcohol-associated hepatitis (AH) has today (May 21) been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA).
SamaCare, a leading cloud-based patient access platform for specialty medications, today announced the closure of an oversubscribed $17 million Series B investment round.
Inato, the global clinical trial marketplace, recently announced the results from a survey of clinical research sponsors and sites to find out what the frustrations were, why the disappointing outcomes were so frequent - and crucially what the sponsors...
Indica Labs, a leader in digital pathology solutions, has announced that it has received FDA clearance for its enterprise digital pathology platform, HALO AP Dx, for primary diagnosis.
Hazel Jones is the CEO at Enhanc3D Genomics. We sat down with her to discuss her leap of faith into 3D genomics, and how she is scaling the business and driving operational change.
Today (May 14) Everest Medicines, a biopharmaceutical company focused on progressive medicines and vaccines, announced the successful launch of small molecule Nefecon, a delayed-release capsule, in China, with the first prescription issued.
The Global Heart Hub, an international alliance of heart patient organizations based in Ireland, has unveiled the first findings from their patient-led Insights from Patients living with Elevated Cholesterol (IPEC) data generation program.
Novigenix, a force in innovative cancer diagnostics, has announced a landmark partnership with the IMMUcan Consortium, a European leader in cancer research.
Sanofi, a global pharmaceutical giant, has announced a significant investment of over €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France.
In an interesting development in the field of rare disease therapeutics, Shionogi & Co., Ltd., and Maze Therapeutics, Inc. have sealed an exclusive worldwide license agreement for MZE001, a novel therapeutic candidate aimed at tackling Pompe disease.
